在肯尼亚和塞内加尔健康参与者中比较EuTCV Vi-CRM197单剂与多剂瓶装配方对比Typbar TCV的安全性及非劣效性:一项多中心、观察者盲法、随机、3期研究
该研究在肯尼亚和塞内加尔的两个医学研究所开展多中心、观察者盲法、随机3期非劣效性试验,纳入6月龄至45岁健康参与者3219人,比较单剂和多剂EuTCV Vi-CRM197与Typbar TCV的安全性及免疫原性。结果显示EuTCV在9-12月龄婴儿中28天血清转化率非劣于Typbar TCV,安全性特征相似,支持WHO预认证。
要点
- EuTCV单剂和多剂配方在9-12月龄婴儿中28天血清转化率非劣于Typbar TCV。
- 所有组别不良事件谱相似,均为轻度或中度,无与试验产品相关的严重不良事件。
- 数据支持EuTCV Vi-CRM197的WHO预认证。
核心结论
- EuTCV Vi-CRM197在婴儿接种后28天免疫学上非劣于Typbar TCV,且在肯尼亚和塞内加尔研究的健康婴儿、儿童和成人中安全性和反应原性与Typbar TCV相似。
研究设计与样本
- 多中心、观察者盲法、随机、3期非劣效性研究,在肯尼亚和塞内加尔各一个医学研究所开展。
- 纳入6月龄至45岁无伤寒病史或接种史的健康参与者,分为4个年龄队列。
- 队列1、2、4按10:10:1随机分配至单剂EuTCV、多剂EuTCV或Typbar TCV;队列3按12:5:5随机分配,多剂组再按1:1:1随机分配至三个批次。
- 共筛查4149人,随机分配3219人(女性1698人[52.7%],男性1521人[47.3%])至单剂EuTCV(n=1266)、多剂EuTCV(n=1630)或Typbar TCV(n=323)。
- 主要终点为安全性和接种后28天血清转化率(抗Vi IgG滴度≥4倍升高),非劣效性在队列3符合方案人群中评估,非劣效界值为-10%。
主要发现
- 第8天局部征集性不良事件报告率:多剂组442/1630(27.1%;95% CI 25.0-29.3),单剂组422/1266(33.3%;30.7-36.0),Typbar TCV组92/323(28.5%;23.6-33.7)。
- 所有年龄亚组中报告的不良事件均为轻度(1级)或中度(2级),未报告与试验产品相关的严重不良事件。
- 队列3接种后28天血清转化率:单剂EuTCV组197/197(100%),多剂EuTCV组551/553(99.6%),Typbar TCV组198/202(98.0%)。
- 与Typbar TCV相比血清转化率差值:单剂组1.98%(95% CI 0.06-3.90),多剂组1.62%(-0.37-3.60)。
关键数值与推荐
- 非劣效界值为血清转化率差值-10%。
- 单剂EuTCV组血清转化率差值1.98%(95% CI 0.06-3.90),多剂组1.62%(-0.37-3.60),均未低于-10%界值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Typhoid is an important global public health problem, despite efforts to enhance access to clean water and sanitation facilities, appropriate diagnostics, treatments, and vaccines. We aimed to assess the safety and non-inferiority of single-dose and multidose EuTCV Vi-CRM197 typhoid conjugate vaccine (TCV) formulations compared with Typbar TCV. METHODS: This multicentre, observer-blinded, randomised, phase 3, non-inferiority study conducted at one medical research institute in Kenya and one in Senegal enrolled healthy participants aged 6 months to 45 years, without previous typhoid or typhoid vaccination, into age-dependent cohorts (cohort 1: 18 years to 45 years; cohort 2: 2 years to <18 years; cohort 3: 9 months to 12 months; cohort 4: 6 months to <9 months or >12 months to <24 months). Participants in cohorts 1, 2, and 4 were randomly assigned 10:10:1 to single-dose EuTCV, multidose EuTCV, or Typbar TCV, and those in cohort 3 were randomly assigned 12:5:5 via an interactive web response system to single-dose EuTCV, multidose EuTCV, or Typbar TCV, with those in the multidose group further randomly assigned 1:1:1 to one of three lots of EuTCV, using block randomisation within-cohort, stratified by site. A single masked 0·5 mL dose of TCV was administered by intramuscular injection. Infants aged 9-12 months received TCV co-administered with yellow fever and measles-rubella vaccines. All participants and trial staff, except for vaccine administrators and pharmacists, were masked to allocation. The primary endpoints were safety, which was analysed in all vaccinated participants for whom safety data were available, and seroconversion (ie, ≥4-fold increase in anti-Vi IgG titres) 28 days post-vaccination, which was evaluated for non-inferiority in the per-protocol population of cohort 3 (ie, infants aged 9-12 months without protocol deviations and with baseline seronegative results), with a non-inferiority margin of -10% for the difference in seroconversion versus Typbar TCV. This trial was registered with the Pan-African Clinical Trials Registry (PACTR202112680671189; now completed). FINDINGS: Between May 3, 2022, and June 21, 2023, 4149 participants were screened, of whom 3219 (1698 [52·7%] female and 1521 [47·3%] male) were randomly assigned to single-dose EuTCV (n=1266), multidose EuTCV (n=1630), or Typbar TCV (n=323). 68 participants (six in cohort 1, 47 in cohort 3, and 15 in cohort 4) withdrew after vaccination or were lost to follow-up, but all were included in the safety population. The adverse events profile across groups was similar (local solicited adverse events by day 8 were reported by 442 [27·1%; 95% CI 25·0-29·3] of 1630 in the multidose group, 422 [33·3%; 30·7-36·0] of 1266 in the single-dose group, and 92 [28·5%; 23·6-33·7] in the Typbar TCV group. All adverse events reported were mild (grade 1) or moderate (grade 2) in all age subsets, and no serious adverse events related to the investigational product were reported. In cohort 3, the seroconversion rate 28 days after vaccination for single-dose (197 [100%] of 197) and multidose (551 [99·6%] of 553) EuTCV was non-inferior to Typbar TCV (198 [98·0%] of 202), with a difference in seroconversion rate versus Typbar TCV of 1·98% (95% CI 0·06 to 3·90) in the single-dose group and 1·62% (-0·37 to 3·60) in the multidose group. INTERPRETATION: These data show that EuTCV Vi-CRM197 is immunologically non-inferior to Typbar TCV in infants 28 days after vaccination and that the overall safety and reactogenicity profiles in healthy infants, children, and adults studied in Kenya and Senegal were similar to Typbar TCV. These data support WHO prequalification. FUNDING: EuBiologics and the RIGHT Foundation. TRANSLATIONS: For the French translation of the abstract see Supplementary Materials section.
引用
- Ndiaye BP, Koech L, Mercer LD, et al. Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study. Lancet Glob Health. 2025. PMID: 41240950. doi:10.1016/S2214-109X(25)00330-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。